Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07224711 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery

Study acronym: IMPALA ERAS
StatusNot Yet Recruiting
PhasePhase 4
Started2026-10-31
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later May 30, 2028 → Oct 31, 2028
See other at-risk trials from Vanderbilt University Medical Center

Amendment history

2026-08-09
Study Status v2
Primary completion pushed: 2028-05-30 → 2028-10-31
Completion pushed: 2028-05-30 → 2028-10-31
Start date2026-07-01→2026-10-31
2026-03-18
Study Identification, Study Status, Study Description, Outcome Measures, Eligibility v1
Start date2026-06-01→2026-07-01
Eligibility criteria-60 characters
[...] siologists (ASA) class II-IV Presenting for major elective, abdominalnon-cardiac surgery on the colorectal, emergency general surgery, urolo [...] o study drug administration Same day surgery Pregnancy (all womenfemale patient of childbearingchild-bearing potentialage arewill alreadyundergo testeda aspregnancy standardtest of carethe day of surgery and will be excluded from this study if found to be pregnant)
Primary endpoints1 to 2 entries
Total Inpatient opioid consumption
Study title+2 characters
The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After AbdominalNon-Cardiac Surgery
2025-11-03
Original filing
The goal of this single-center, pragmatic, randomized, blinded, placebo-controlled trial is to evaluate the impact of intravenous (IV) lidocaine within the existing Enhanced Recovery After Surgery (ERAS)program on outcomes in patients after major non-cardiac surgery. The main questions the trial aims to answer are: The primary hypothesis is that utilization of IV lidocaine as part of a perioperative multimodal pain regimen will result in a reduction in hospital Case Mix Index-Adjusted Resource Length of Stay (CARLOS). The secondary hypotheses are that lidocaine infusion will result in a reduction in total inpatient opioid consumption (oral morphine milligram equivalents, oMMEs) and pain scores, and improved surgical outcomes (including return of bowel function, ileus, nausea, rapid responses called, surgical site infections, and ICU transfers), while also having minimal incidence of side effects (including double/blurry vision, tinnitus, sedation, and adverse events requiring early cessation).
Trial Details
NCT Number NCT07224711
Lead Sponsor Vanderbilt University Medical Center
Conditions Pain, Post Operative Analgesia, Opioid Consumption, Postoperative
Enrollment 2,290 participants
Start Date 2026-10-31
Primary Completion 2028-10-31 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-11